# Plain RAG on Loeys-Dietz syndrome 6 (SMAD2, OMIM:619656)
model: gemini-3.8-flash   generated: 2026-09-28 20:46

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `SMAD2 gene Loeys-Dietz syndrome 6`

[1] **Entry - #619656 - LOEYS-DIETZ SYNDROME 6; LDS6**  
    https://omim.org/entry/619656  
    A number sign (#) is used with this entry because of evidence that Loeys-Dietz syndrome-6 (LDS6) is caused by heterozygous mutation in the SMAD2 gene (601366) ...

[2] **Loeys-Dietz Syndrome 6 (LDS6)**  
    https://www.malacards.org/card/loeys_dietz_syndrome_6  
    It is associated with heterozygous mutation in the SMAD2 gene on chromosome 18q21 and is inherited in an autosomal dominant pattern. ... 104 Mouse Phenotypes for ...

[3] **WHAT IS LDS? | MAIN CHARACTERISTICS | DIAGNOSIS**  
    https://www.loeysdietz.org/en/medical-information  
    LDS is caused by genetic changes affecting the TGF-β signaling pathway. The genes associated with LDS include TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, and TGFB3, as ...

[4] **A mutation update on the LDS‐associated genes TGFB2/3 ...**  
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5947146/  
    by D Schepers · 2018 · Cited by 206 — The Loeys–Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular, skeletal, and ocular system. Most typically, LDS patients present ...

[5] **Genetics**  
    https://loeysdietzcanada.org/about-loeys-dietz-syndrome/genetics/  
    Loeys-Dietz syndrome 6 (LDS6) caused by mutations in the SMAD2 gene (mothers against decapentaplegic homolog 2). Researchers continue to explore if and how the ...

[6] **Autosomal dominant by ClinGen submission information facts**  
    https://thegencc.org/submissions/SGC-107494.4  
    SMAD2 was first reported in relation to autosomal dominant inheritance of Loeys-Dietz syndrome (LDS) and thoracic aortic aneurysm and dissection (TAAD) in 2015 ...

## 2. The context handed to the model
```
[1] Entry - #619656 - LOEYS-DIETZ SYNDROME 6; LDS6
https://omim.org/entry/619656
A number sign (#) is used with this entry because of evidence that Loeys-Dietz syndrome-6 (LDS6) is caused by heterozygous mutation in the SMAD2 gene (601366) ...

[2] Loeys-Dietz Syndrome 6 (LDS6)
https://www.malacards.org/card/loeys_dietz_syndrome_6
It is associated with heterozygous mutation in the SMAD2 gene on chromosome 18q21 and is inherited in an autosomal dominant pattern. ... 104 Mouse Phenotypes for ...

[3] WHAT IS LDS? | MAIN CHARACTERISTICS | DIAGNOSIS
https://www.loeysdietz.org/en/medical-information
LDS is caused by genetic changes affecting the TGF-β signaling pathway. The genes associated with LDS include TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, and TGFB3, as ...

[4] A mutation update on the LDS‐associated genes TGFB2/3 ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC5947146/
by D Schepers · 2018 · Cited by 206 — The Loeys–Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular, skeletal, and ocular system. Most typically, LDS patients present ...

[5] Genetics
https://loeysdietzcanada.org/about-loeys-dietz-syndrome/genetics/
Loeys-Dietz syndrome 6 (LDS6) caused by mutations in the SMAD2 gene (mothers against decapentaplegic homolog 2). Researchers continue to explore if and how the ...

[6] Autosomal dominant by ClinGen submission information facts
https://thegencc.org/submissions/SGC-107494.4
SMAD2 was first reported in relation to autosomal dominant inheritance of Loeys-Dietz syndrome (LDS) and thoracic aortic aneurysm and dissection (TAAD) in 2015 ...
```

## 3. The gene, from the sources

The *SMAD2* gene, which encodes mothers against decapentaplegic homolog 2, is located on chromosome 18q21 [2, 5]. In the cell, *SMAD2* functions as part of the TGF-β signaling pathway, although deeper molecular details regarding its specific gene product and cellular mechanisms are not covered in the provided sources [3]. 

Heterozygous mutations in the *SMAD2* gene cause Loeys-Dietz syndrome 6 (LDS6), which is inherited in an autosomal dominant pattern [1, 2, 6]. Disease occurs because these genetic alterations affect the broader TGF-β signaling pathway, and *SMAD2* variants are also associated with thoracic aortic aneurysm and dissection [3, 6]. Clinically, Loeys-Dietz syndrome manifests as a connective tissue disorder impacting the cardiovascular, ocular, and skeletal systems [4]. Beyond impacting the TGF-β pathway, the exact mechanisms of how these mutations cause disease are not fully detailed in the sources, as researchers continue to explore if and how they operate [3, 5].

*tokens in 593, out 1593*

## 4. The gene, closed book (no sources; beware hallucinations)

The ***SMAD2*** gene encodes Mothers Against Decapentaplegic Homolog 2 (SMAD2), an intracellular receptor-regulated effector protein (R-SMAD) in the canonical transforming growth factor-beta (TGF-β) and activin signaling cascades. Upon phosphorylation by the activated TGF-β type I receptor, SMAD2 binds to the co-factor SMAD4 and translocates into the nucleus to regulate the transcription of target genes critical for extracellular matrix (ECM) remodeling, cell growth, and vascular development.

Heterozygous loss-of-function variants—typically missense mutations clustered in the conserved MH2 domain—impair SMAD2 activation or DNA binding. Paradoxically, this primary signaling defect triggers secondary, compensatory hyperactivation of downstream TGF-β signaling in

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P06)

Based on the provided sources, here is the clinical evaluation:

### 1. Patient Rule-In / Rule-Out Evaluation

* **P01:** Cannot be ruled in or ruled out. The sources state that LDS affects the cardiovascular, skeletal, and ocular systems [4], which are present here, but the sources do not provide full phenotypic criteria or exclusion criteria for LDS6 (*SMAD2*) [1–6].
* **P02:** Cannot be ruled in or ruled out. Although congenital heart defects are present, the sources do not state the exclusionary criteria or full clinical spectrum of LDS6 [1–6].
* **P03:** Cannot be ruled in or ruled out. This patient has aortic dissection, which matches the mention of thoracic aortic aneurysm and dissection (TAAD) associated with *SMAD2* [6], as well as skeletal involvement [4], but the sources do not provide definitive diagnostic criteria to confirm or exclude LDS6 [1–6].
* **P04:** Cannot be ruled in or ruled out. The sources do not provide phenotypic criteria to rule this patient in or out [1–6].
* **P05:** Cannot be ruled in or ruled out. The patient has ocular and skeletal findings consistent with general connective tissue involvement [4], but the sources do not specify the exact phenotype needed to rule LDS6 in or out [1–6].
* **P06:** Cannot be ruled in or ruled out. The patient features "Thoracic aortic aneurysm", an exact match for the TAAD phenotype associated with *SMAD2* [6], along with skeletal and craniofacial/ocular findings [4], but the sources lack comprehensive diagnostic criteria to rule P06 in definitively or rule others out [1–6].
* **P07:** Cannot be ruled in or ruled out. Skeletal, cardiovascular, and ocular features are present [4], but the sources do not provide sufficient detail to rule LDS6 in or out [1–6].
* **P08:** Cannot be ruled in or ruled out. The patient presents with aortic dissection, fitting the *SMAD2* TAAD association [6], and craniofacial/ocular involvement [4], but the sources lack specific criteria to confirm or exclude LDS6 [1–6].
* **P09:** Cannot be ruled in or ruled out. Connective tissue, cardiovascular, and skeletal features are present [4], but the sources do not provide sufficient phenotypic profiles to confirm or exclude LDS6 [1–6].
* **P10:** Cannot be ruled in or ruled out. The sources do not provide diagnostic or exclusionary profiles for LDS6 [1–6].

---

### 2. Most Likely Patient and Estimated Probability

* **Most Likely Patient:** **P06**
  * *Reasoning:* Source [6] explicitly identifies *SMAD2* with autosomal dominant Loeys-Dietz syndrome and "thoracic aortic aneurysm and dissection (TAAD)" [6], and source [4] notes that LDS affects the cardiovascular, skeletal, and ocular systems [4]. P06 is the only patient with the explicit term **"Thoracic aortic aneurysm"** alongside skeletal ("High palate", "Tall stature") and ocular/craniofacial ("Hypertelorism") features [4, 6].
* **Probability:** **Indeterminate from the text (approximately 20–30%)**.
  * *Reasoning:* Because the sources do not provide detailed phenotypic frequencies or exclusion criteria, an exact probability cannot be mathematically calculated from the text alone. Since there are 10 candidates (base rate 10%) and multiple patients share overlapping TAAD-spectrum features (such as P03 and P08 having aortic dissection [6]), P06 is only marginally favored due to the verbatim match with "Thoracic aortic aneurysm" [6].

---

### 3. Missing Facts Needed for Confidence

To make a definitive and confident determination, the following missing information is required:
1. **Genetic data:** Confirmation of a heterozygous pathogenic variant in the *SMAD2* gene for the specific patient [1, 2, 5, 6].
2. **Detailed clinical diagnostic criteria:** A definitive list of core phenotypic features and diagnostic thresholds specifically established for LDS6 [1–6].
3. **Exclusionary criteria / Differential diagnosis:** Information distinguishing LDS6 from other LDS subtypes (associated with *TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3*) [3] or related disorders (e.g., Marfan syndrome, vascular Ehlers-Dietz/Ehlers-Danlos phenotypes).
4. **Phenotypic prevalence data:** Frequencies of specific HPO findings (such as bifid uvula, arterial tortuosity, or ectopia lentis) among individuals with confirmed *SMAD2* mutations [1–6].

--------------------------------------------------------------------------------

### Round 2  (picked: P06)

### 1. Patient Evaluation (Rule-In / Rule-Out)

The provided sources state that Loeys-Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular, skeletal, and ocular systems [4], and that heterozygous mutations in *SMAD2* cause LDS6, which was first reported in association with thoracic aortic aneurysm and dissection (TAAD) [1, 2, 5, 6]. 

However, **the sources do not provide detailed phenotypic descriptions, diagnostic criteria, or exclusion criteria for LDS6 or any other condition** [1–6]. Consequently, the sources **do not allow us to definitively rule in or rule out any of the 10 patients** [1–6]. Below is the evaluation for each patient based strictly on what the sources state:

* **P01**: **Cannot rule in or rule out.** The patient has cardiovascular, skeletal, and ocular findings, which broadly align with systems affected in LDS [4]. However, the sources provide no information about features like lipodystrophy, progeroid appearance, or ectopia lentis in LDS6 to confirm or exclude this diagnosis [1–6].
* **P02**: **Cannot rule in or rule out.** While cardiovascular and skeletal features are present [4], there are no reported ocular findings or thoracic aortic aneurysm/dissection [4, 6]. Nonetheless, the sources do not state that such features exclude LDS6 [1–6].
* **P03**: **Cannot rule in or rule out.** The patient has aortic dissection and aortic aneurysm, fitting the cardiovascular involvement and TAAD association described for *SMAD2* [4, 6], as well as skeletal involvement [4]. However, the sources lack sufficient detail to confirm LDS6 over other conditions [1–6].
* **P04**: **Cannot rule in or rule out.** The patient presents with craniofacial and endocrine features but lacks documented cardiovascular, skeletal, or ocular involvement [4, 6]. The sources do not provide exclusion criteria to rule P04 out definitively [1–6].
* **P05**: **Cannot rule in or rule out.** The patient exhibits skeletal and ocular involvement [4], but lacks documented cardiovascular involvement or TAAD [4, 6]. Because the sources do not state that TAAD is mandatory in every individual, P05 cannot be definitively ruled out [1–6].
* **P06**: **Cannot rule in or rule out definitively**, but has features consistent with the sources. The patient has cardiovascular involvement explicitly matching "thoracic aortic aneurysm" [6], skeletal involvement ("High palate", "Tall stature") [4], and ocular/craniofacial involvement ("Hypertelorism") [4]. Definitive rule-in is not possible because the sources omit full clinical criteria [1–6].
* **P07**: **Cannot rule in or rule out.** The patient demonstrates cardiovascular, skeletal, and ocular involvement [4], but the sources provide no data to confirm or exclude LDS6 based on this profile [1–6].
* **P08**: **Cannot rule in or rule out.** The patient has aortic dissection/aneurysm matching TAAD [6] and ocular/craniofacial features [4], but the sources lack granular clinical descriptions to differentiate this from other causes [1–6].
* **P09**: **Cannot rule in or rule out.** Displays cardiovascular, skeletal, and ocular findings [4], but the sources do not provide the phenotypic detail necessary to confirm or exclude LDS6 [1–6].
* **P10**: **Cannot rule in or rule out.** Displays vascular fragility ("Arterial rupture") and connective tissue signs [4, 6], but the sources do not specify whether this pattern is consistent with or diagnostic of LDS6 [1–6].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient:** **P06**
* **Estimated Probability:** **~60%**

**Reasoning:**  
Source [6] explicitly associates *SMAD2* with autosomal dominant inheritance of Loeys-Dietz syndrome and "thoracic aortic aneurysm and dissection (TAAD)" [6]. P06 is the only patient whose phenotypic profile specifically includes the term **"Thoracic aortic aneurysm"** as stated in [6], alongside concurrent involvement of the cardiovascular system ("Dilatation of the cerebral artery"), skeletal system ("High palate", "Tall stature"), and ocular/craniofacial region ("Hypertelorism"), fully matching the multi-system involvement outlined in [4]. Because the provided sources do not rule out the other patients who also exhibit aneurysm or dissection (such as P01, P03, and P08) [4, 6], confidence is limited, warranting an estimated probability of approximately 60%.

---

### 3. Missing Facts Needed for Confidence

To make a definitive and confident clinical genetics diagnosis, the following information—which is entirely absent from the provided sources—is required:

1. **Complete clinical phenotypic spectrum of LDS6:** The sources do not detail the characteristic or distinguishing dysmorphic, vascular, skeletal, or ocular features of *SMAD2*-related LDS [1–6].
2. **Specific diagnostic and exclusion criteria:** The sources do not state mandatory diagnostic findings or exclusionary phenotypes for LDS6 [1–6].
3. **Differential diagnostic comparison across LDS types:** The sources list genes associated with LDS (*TGFBR1*, *TGFBR2*, *SMAD2*, *SMAD3*, *TGFB2*, *TGFB3*) [3] but do not provide phenotypic features that distinguish *SMAD2* (LDS6) from the other subtypes or from related disorders (e.g., Marfan syndrome, vascular Ehlers-Danlos syndrome) [1–6].
4. **Complete text of the cited entries:** Key clinical descriptions in sources [1], [4], and [6] are truncated (e.g., [4] truncates right at *"Most typically, LDS patients present ..."*), withholding critical phenotypic data [1, 4, 6].

--------------------------------------------------------------------------------

### Round 3  (picked: P06)

### 1. Patient Evaluation (Rule In / Rule Out)

The provided sources establish that Loeys-Dietz syndrome 6 (LDS6) is an autosomal dominant connective tissue disorder caused by heterozygous mutations in the *SMAD2* gene [1, 2, 5, 6], affects the cardiovascular, skeletal, and ocular systems [4], and is associated with thoracic aortic aneurysm and dissection (TAAD) [6]. However, the sources **do not provide** full phenotypic descriptions, detailed Human Phenotype Ontology (HPO) profiles, or formal diagnostic/exclusion criteria for LDS6 [1–6]. 

Consequently, the sources do not contain sufficient clinical detail to conclusively rule in or rule out any individual patient:

* **P01:** **Cannot rule in or rule out.** The patient has cardiovascular (aortic root aneurysm), skeletal, and ocular features consistent with general LDS systems [4], but the sources do not state whether progeroid features, lipodystrophy, or intrauterine growth retardation can occur in or exclude LDS6 [1–6].
* **P02:** **Cannot definitively rule out, cannot rule in.** The patient lacks the thoracic aortic aneurysm and dissection (TAAD) associated with *SMAD2* [6] and presents with complex congenital heart defects (levotransposition of the great arteries, situs ambiguus) not mentioned in the sources [1–6]; however, the sources do not list explicit exclusion criteria to formally rule P02 out [1–6].
* **P03:** **Cannot rule in or rule out.** The patient has aortic root aneurysm, aortic dissection, and skeletal findings, fitting the cardiovascular and skeletal involvement described in [4, 6], but the sources do not specify the exact craniofacial or extremity features of LDS6 needed to rule them in or out [1–6].
* **P04:** **Cannot definitively rule out, cannot rule in.** The patient displays craniofacial findings, hypoparathyroidism, and sensorineural hearing impairment, but lacks cardiovascular/TAAD features [4, 6]. The sources do not provide negative criteria to formally rule P04 out [1–6].
* **P05:** **Cannot rule in or rule out.** The patient exhibits skeletal and ocular involvement [4], but lacks the aortic aneurysm/dissection specifically linked to *SMAD2* [6]. The sources do not state whether absence of TAAD rules out LDS6 [1–6].
* **P06:** **Cannot conclusively rule in or rule out.** The patient possesses the exact cardinal manifestation linked to *SMAD2*—"Thoracic aortic aneurysm" [6]—as well as skeletal findings ("High palate", "Tall stature") [4]. However, the sources do not provide the complete phenotypic spectrum of LDS6 to definitively rule P06 in, nor any basis to rule them out [1–6].
* **P07:** **Cannot rule in or rule out.** The patient exhibits skeletal, ocular, and arterial involvement [4], but the sources do not specify whether LDS6 involves this specific constellation of features [1–6].
* **P08:** **Cannot rule in or rule out.** The patient presents with aortic root aneurysm and aortic dissection, which align with cardiovascular/TAAD involvement [4, 6], but the sources do not provide distinguishing criteria between LDS6 and other LDS types [1–6].
* **P09:** **Cannot rule in or rule out.** The patient has aortic root aneurysm and skeletal features [4], but the sources lack the phenotypic detail needed to confirm or exclude LDS6 [1–6].
* **P10:** **Cannot rule in or rule out.** The patient displays vascular rupture and joint hypermobility [4], but the sources do not state whether this specific clinical presentation is consistent with or excludes LDS6 [1–6].

---

### 2. Most Likely Patient and Estimated Probability

* **Most Likely Patient:** **P06**
* **Estimated Probability:** **60%**

**Reasoning:** Source [6] explicitly links *SMAD2* to autosomal dominant LDS presenting with "thoracic aortic aneurysm and dissection (TAAD)" [6], and Source [4] identifies LDS as a connective tissue disorder involving the cardiovascular and skeletal systems [4]. P06 is the only patient presenting with the verbatim term **"Thoracic aortic aneurysm"** alongside typical skeletal/connective tissue manifestations ("Tall stature", "High palate", "Striae distensae") [4, 6]. A higher probability cannot be assigned because P03 and P08 also have aortic aneurysms/dissections [4, 6], and the sources do not provide granular phenotypic series to definitively separate them [1–6].

---

### 3. Facts Needed to Be Confident (Not Provided in the Sources)

To establish a confident diagnosis, the following information—which is absent from the provided text—is required:
1. **Molecular Genetic Data:** Confirmation of a heterozygous pathogenic variant in the *SMAD2* gene for the specific patient [1, 2, 5, 6].
2. **Comprehensive Phenotypic Synopsis of LDS6:** The full clinical synopsis and HPO term mapping from OMIM #619656 (the excerpt in [1] truncates after the gene name and does not list clinical features) [1].
3. **Differential Diagnostic / Exclusionary Criteria:** Specific clinical rules distinguishing LDS6 (*SMAD2*) from other LDS types caused by *TGFBR1*, *TGFBR2*, *SMAD3*, *TGFB2*, and *TGFB3* [3], as well as from other related connective tissue disorders (e.g., Marfan syndrome, vascular Ehlers-Danlos syndrome) [4].
4. **Family History and Inheritance:** Documentation of an autosomal dominant inheritance pattern in the patient's pedigree [2, 6].

--------------------------------------------------------------------------------

picks across rounds: ['P06', 'P06', 'P06']
